37
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Probiotics have beneficial metabolic effects in patients with type 2 diabetes mellitus: a meta-analysis of randomized clinical trials

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Probiotics have been reported to have a positive impact on the metabolic control of patients with type 2 diabetes. We aimed to systematically evaluate the effects of probiotics on cardiometabolic parameters in type 2 diabetes based on randomized controlled studies. MEDLINE, Embase, and CENTRAL databases were reviewed to search for randomized controlled trials that examined the effects of probiotic supplementation on cardiometabolic parameters in patients with type 2 diabetes. 32 trials provided results suitable to be included in the analysis. The effects of probiotics were calculated for the following parameters: BMI, total cholesterol levels, LDL, triglycerides, HDL, CRP, HbA1c levels, fasting plasma glucose, fasting insulin levels, systolic and diastolic blood pressure values. Data analysis showed a significant effect of probiotics on reducing total cholesterol, triglyceride levels, CRP, HbA1c, fasting plasma glucose, fasting insulin levels, and both systolic and diastolic blood pressure values. Supplementation with probiotics increased HDL levels however did not have a significant effect on BMI or LDL levels. Our data clearly suggest that probiotics could be a supplementary therapeutic approach in type 2 diabetes mellitus patients to improve dyslipidemia and to promote better metabolic control. According to our analysis, probiotic supplementation is beneficial in type 2 diabetes mellitus.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040.

          To produce current estimates of the national, regional and global impact of diabetes for 2015 and 2040.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The core gut microbiome, energy balance and obesity.

            Metagenomics is an emerging field focused on characterizing the structures, functions and dynamic operations of microbial communities sampled in their native habitats without the need for culture. Here, we present findings from a 16S rRNA gene sequence- and whole community DNA shotgun sequencing-based analysis of the adult human gut microbiomes of lean and obese mono- and dizygotic twins. Our findings indicate that a core microbiome can be found at the gene level, despite large variation in community membership, and that variations from the core are associated with obesity. These findings have implications for ongoing Human Microbiome Project(s), and highlight important challenges to the field of metagenomics.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management

              Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas. T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations. In this mini review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM.
                Bookmark

                Author and article information

                Contributors
                margit.solymar@aok.pte.hu
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                16 July 2020
                16 July 2020
                2020
                : 10
                : 11787
                Affiliations
                [1 ]ISNI 0000 0001 0663 9479, GRID grid.9679.1, Institute for Translational Medicine, Medical School, , University of Pécs, ; 12 Szigeti str., Pecs, 7624 Hungary
                [2 ]ISNI 0000 0001 1016 9625, GRID grid.9008.1, Hungarian Academy of Sciences, , University of Szeged, Momentum Gastroenterology Multidisciplinary Research Group, ; Szeged, Hungary
                [3 ]ISNI 0000 0001 0663 9479, GRID grid.9679.1, Szentágothai Research Center, , University of Pécs, ; Pecs, Hungary
                [4 ]ISNI 0000 0001 0663 9479, GRID grid.9679.1, Heart Institute, Medical School, , University of Pécs, ; Pecs, Hungary
                Article
                68440
                10.1038/s41598-020-68440-1
                7366719
                31913322
                f9bb2cbb-1ccc-4dbb-9fc9-3b2348b519aa
                © The Author(s) 2020

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 26 April 2020
                : 23 June 2020
                Funding
                Funded by: Human Resources Development Operational Programme Grant
                Award ID: EFOP 3.6.2-16-2017-00006
                Funded by: FundRef http://dx.doi.org/10.13039/501100008530, European Regional Development Fund;
                Award ID: GINOP-2.3.2-15-2016-00048
                Funded by: New National Excellence Program of the Hungarian Ministry of Human Capacities
                Award ID: UNKP-19-4-PTE-236
                Categories
                Article
                Custom metadata
                © The Author(s) 2020

                Uncategorized
                diabetes,dyslipidaemias
                Uncategorized
                diabetes, dyslipidaemias

                Comments

                Comment on this article